[-] Show simple item record

dc.contributor.authorPrice, Davideng
dc.contributor.authorBetancourt, Victoriaeng
dc.contributor.authorKaufman, Leonoraeng
dc.date.issued2007-03eng
dc.description.abstractTopical mupirocin (Bactroban) and fusidic acid (not available in the United States) are more effective than placebo and at least as effective as oral antibiotics for the treatment of limited impetigo, and are better tolerated. (Strength of recommendation [SOR]: A) Based on the available evidence on effectiveness, no clear preference can be given for any one oral antibiotic over another. (SOR: A)eng
dc.identifier.citationAmerican Family Physician, 75(5) 2007.eng
dc.identifier.urihttp://hdl.handle.net/10355/3980eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2007 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectskin infectioneng
dc.subjectetiologic agenteng
dc.subjectantiseptic agentseng
dc.subjectantibiotic resistanceeng
dc.subject.lcshImpetigo -- Treatmenteng
dc.subject.lcshMupirocineng
dc.subject.lcshStreptococcal infectionseng
dc.titleTreatment of Impetigoeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record